Aca­d­e­m­ic tri­al sug­gests mod­est GLP-1 ef­fect in Parkin­son's dis­ease, but ques­tions re­main

New da­ta from a French aca­d­e­m­ic tri­al pub­lished in the New Eng­land Jour­nal of Med­i­cine on Wednes­day sug­gest the po­ten­tial for treat­ing Parkin­son’s dis­ease with a GLP-1 ag­o­nist.

The im­pact so far is mod­est, and in­ves­ti­ga­tors cau­tion that im­por­tant ques­tions re­main. But the study adds to the grow­ing body of re­search in­di­cat­ing how the GLP-1 drug class, with which No­vo Nordisk and Eli Lil­ly have built emerg­ing fran­chis­es in di­a­betes and obe­si­ty, can po­ten­tial­ly treat a wide range of con­di­tions from kid­ney and heart dis­ease to sleep ap­nea and de­pres­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.